Therapix Biosciences and the Hannover Medical School Enter into an Investigator-initiated Clinical Trial Agreement to Assess the Effect of TXH-TS01 in Patients with Tourette Syndrome TEL AVIV, Israel, May...

Therapix Signs Exclusive License Agreement with Yissum for Nasal Drug Delivery Technology Agreement Paves the Way for Development and Marketing of New Cannabinoid-based Treatment Offerings for Mild Cognitive Impairment...

Therapix Biosciences Ltd. Announces Pricing of U.S. Initial Public Offering and NASDAQ Listing TEL AVIV, Israel, March 22, 2017 /PRNewswire/ — Therapix Biosciences Ltd. (NASDAQ: TRPX) (TASE: THXBY), a...

Therapix Biosciences announces enrollment of the first patient for clinical trial at Yale University for treating Tourette’s syndrome using cannabinoid-based drug TEL AVIV, Israel, January 4, 2017 /PRNewswire/ —...